Razia Hashmi, chief medical officer at the Blue Cross Blue Shield Association, put it bluntly: "The current insurance construct was not designed to handle this kind of demand." She was right
Klebanoff answered questions about his findings below
[DOI] [PMC free article] [PubMed] [Google Scholar] 34.Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial
Reply This particular GLP-1 Program is specific to weight-loss indications, because drugs prescribed for weight management generally cannot be covered by Part D plans under federal law
The length of this therapy is dictated by your weight and how fast your body responds to the treatment
Every product is supplied strictly for laboratory and academic research and is not for human consumption, diagnosis, or treatment
